|
David Chaplin Ph.D. has been a leader in the field of vascular targeting for the last 10 years and is one of the original discoverers of Combretastatin. His original work formed the basis for not only the development of Combretastatin A4 Prodrug with OXiGENE but also the subsequent vascular targeting development programs at AstraZeneca and Aventis. Dr. Chaplin has more than 18 years of experience in oncology research. Most recently Dr. Chaplin was Vice President Oncology at Aventis Pharma in Paris. Prior to the merger of Rhone Poulenc Rorer (RPR) with Hoechst Marion Roussell Dr. Chaplin was Senior Director of Oncology at RPR from 1998 to 1999. From 1992 to 1998 Dr. Chaplin led the Cancer Research Campaign's (CRC) Tumor Microcirculation Group based at the Gray Laboratory Cancer Research Trust Mount Vernon Hospital London. Dr. Chaplin has also served as Section Head of Cancer Biology at Xenova in the UK and has held a senior staff appointment at the British Columbia Cancer Research Centre. Educated in the United Kingdom Dr. Chaplin has a B.Sc. in chemistry from the University of Essex a M.Sc. in pharmacology from the University of Southampton and completed his Ph.D. in tumor biology at the University of London. | 